Clinical Trials Logo

Laryngeal Carcinoma clinical trials

View clinical trials related to Laryngeal Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06080503 Recruiting - Laryngeal Carcinoma Clinical Trials

Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy

Start date: March 14, 2024
Phase: N/A
Study type: Interventional

To compare the acute tolerance of highly conformal hypofractionated versus conventional radiotherapy.

NCT ID: NCT05568641 Not yet recruiting - Laryngeal Carcinoma Clinical Trials

Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma

Start date: January 2023
Phase:
Study type: Observational

Laryngeal squamous cell carcinoma (LSCC) is the second most common primary malignant tumor of the respiratory tract after lung cancer and the second most common primary epithelial malignant tumor of the head and neck. The age of onset of LSCC is mostly between 50 and 70 years, with a male to female ratio of approximately 4:1 .According to estimates by the American Cancer Society, in the United States, approximately 12,470 new cases of laryngeal cancer will be diagnosed and 3,820 people will die from laryngeal cancer in 2022. The nuclear vitamin D receptor (VDR) is involved in multiple pathways that have many points of convergence. Some of these pathways are implicated in carcinogenesis thus the suggestion that VDR has a role to play in the biology of cancer [3]. Recent evidence indicates that the active form of vitamin D (1alpha, 25-dihydroxycholecalciferol) (VD) exhibits several different effects on normal and cancerous cells, including up-regulation of anti- proliferation and pro-apoptotic factors, as well as inhibition of cell-cycle promoters and growth factor signaling pathways. Thus it is useful as an anti-neoplastic agent in several human malignancies. Studies in cell and animal model systems, as well as clinical trials have recognized the potential usefulness of VD and VD analogues as agents that enhance the anti-proliferative/cytotoxic effects of chemotherapy and ionizing radiation. Thus, at concentrations that produce limited hypercalcemia, these agents may be used as adjuncts to conventional chemotherapy and radiotherapy. We aim to analyze the expression of VDR in LSCC to determine potential for active VD therapy in such patients.

NCT ID: NCT05075980 Recruiting - Clinical trials for Head and Neck Carcinoma

HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers

Start date: February 16, 2022
Phase: Phase 2
Study type: Interventional

This clinical trial tests whether intensity modulated proton therapy after surgery works to shrink tumors in patients with head and neck cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors.

NCT ID: NCT04788264 Completed - Lung Carcinoma Clinical Trials

Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment

Start date: March 28, 2021
Phase: N/A
Study type: Interventional

This clinical trial evaluates the tolerability of a physical activity program in head and neck cancer patients who are undergoing cancer treatment. The goal of this trial is to give patients exercises prescribed by a physical therapist that they are able to complete regularly at home. Increasing physical activity may help patients reduce fatigue, improve mood, increase physical performance, and decrease joint pain.

NCT ID: NCT03132727 Completed - Laryngeal Carcinoma Clinical Trials

Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer

Larynx MRI
Start date: March 23, 2017
Phase:
Study type: Observational

To determine if MRI can detect preoperative invasion of cartilage by laryngeal and hypopharyngeal carcinoma, and to compare it to CT imaging and histopathology in excised larynges and/or hypopharynges.

NCT ID: NCT02587546 Completed - Laryngeal Carcinoma Clinical Trials

Thulium Contact Laser of Laryngotracheal Stenosis

Start date: October 2015
Phase: N/A
Study type: Interventional

The purpose of the study is to compare results of the treatment of tumorous and non-tumorous laryngotracheal stenosis using thulium contact laser versus carbon dioxide laser used in the past.

NCT ID: NCT02062632 Terminated - Lymphoma Clinical Trials

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

Start date: April 14, 2014
Phase: Phase 2
Study type: Interventional

This randomized pilot clinical trial studies the effects of taking doxepin hydrochloride as compared to placebo (inactive drug) in treating esophageal pain in patients with cancer located in the chest area receiving radiation therapy to the thorax with or without chemotherapy. Doxepin hydrochloride is a tricyclic antidepressant drug which was recently shown to be helpful for mouth pain in patients receiving radiation therapy. Doxepin hydrochloride affects the surface of the esophagus, which may be helpful in reducing the pain caused by radiation therapy.